View in EDS

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.

Saved in:
Bibliographic Details
Title: Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Authors: Horn, Leora1 leora.horn@vanderbilt.edu, Gettinger, Scott2 scott.gettinger@yale.edu, Camidge, D. Ross3 ross.camidge@ucdenver.edu, Smit, Egbert F.4 EF.Smit@vumc.nl, Janjigian, Yelena Y.5 janjigiy@mskcc.org, Miller, Vincent A.6 vmiller@foundationmedicine.com, Pao, William1 william.pao@vanderbilt.edu, Freiwald, Matthias7 matthias.freiwald@boehringer-ingelheim.com, Fan, Jean8 jean.fan@boehringer-ingelheim.com, Wang, Bushi8 bushi.wang@boehringer-ingelheim.com, Chand, Vikram K.8 vikramkchand@gmail.com, Groen, Harry J.M.9 h.j.m.groen@umcg.nl
Source: Lung Cancer (01695002). Nov2017, Vol. 113, p51-58. 8p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 125920839
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Horn%2C+Leora%22">Horn, Leora</searchLink><relatesTo>1</relatesTo><i> leora.horn@vanderbilt.edu</i><br /><searchLink fieldCode="AR" term="%22Gettinger%2C+Scott%22">Gettinger, Scott</searchLink><relatesTo>2</relatesTo><i> scott.gettinger@yale.edu</i><br /><searchLink fieldCode="AR" term="%22Camidge%2C+D%2E+Ross%22">Camidge, D. Ross</searchLink><relatesTo>3</relatesTo><i> ross.camidge@ucdenver.edu</i><br /><searchLink fieldCode="AR" term="%22Smit%2C+Egbert+F%2E%22">Smit, Egbert F.</searchLink><relatesTo>4</relatesTo><i> EF.Smit@vumc.nl</i><br /><searchLink fieldCode="AR" term="%22Janjigian%2C+Yelena+Y%2E%22">Janjigian, Yelena Y.</searchLink><relatesTo>5</relatesTo><i> janjigiy@mskcc.org</i><br /><searchLink fieldCode="AR" term="%22Miller%2C+Vincent+A%2E%22">Miller, Vincent A.</searchLink><relatesTo>6</relatesTo><i> vmiller@foundationmedicine.com</i><br /><searchLink fieldCode="AR" term="%22Pao%2C+William%22">Pao, William</searchLink><relatesTo>1</relatesTo><i> william.pao@vanderbilt.edu</i><br /><searchLink fieldCode="AR" term="%22Freiwald%2C+Matthias%22">Freiwald, Matthias</searchLink><relatesTo>7</relatesTo><i> matthias.freiwald@boehringer-ingelheim.com</i><br /><searchLink fieldCode="AR" term="%22Fan%2C+Jean%22">Fan, Jean</searchLink><relatesTo>8</relatesTo><i> jean.fan@boehringer-ingelheim.com</i><br /><searchLink fieldCode="AR" term="%22Wang%2C+Bushi%22">Wang, Bushi</searchLink><relatesTo>8</relatesTo><i> bushi.wang@boehringer-ingelheim.com</i><br /><searchLink fieldCode="AR" term="%22Chand%2C+Vikram+K%2E%22">Chand, Vikram K.</searchLink><relatesTo>8</relatesTo><i> vikramkchand@gmail.com</i><br /><searchLink fieldCode="AR" term="%22Groen%2C+Harry+J%2EM%2E%22">Groen, Harry J.M.</searchLink><relatesTo>9</relatesTo><i> h.j.m.groen@umcg.nl</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lung+Cancer+%2801695002%29%22">Lung Cancer (01695002)</searchLink>. Nov2017, Vol. 113, p51-58. 8p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=125920839
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.lungcan.2017.08.014
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 8
        StartPage: 51
    Titles:
      – TitleFull: Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Horn, Leora
      – PersonEntity:
          Name:
            NameFull: Gettinger, Scott
      – PersonEntity:
          Name:
            NameFull: Camidge, D. Ross
      – PersonEntity:
          Name:
            NameFull: Smit, Egbert F.
      – PersonEntity:
          Name:
            NameFull: Janjigian, Yelena Y.
      – PersonEntity:
          Name:
            NameFull: Miller, Vincent A.
      – PersonEntity:
          Name:
            NameFull: Pao, William
      – PersonEntity:
          Name:
            NameFull: Freiwald, Matthias
      – PersonEntity:
          Name:
            NameFull: Fan, Jean
      – PersonEntity:
          Name:
            NameFull: Wang, Bushi
      – PersonEntity:
          Name:
            NameFull: Chand, Vikram K.
      – PersonEntity:
          Name:
            NameFull: Groen, Harry J.M.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: Nov2017
              Type: published
              Y: 2017
          Identifiers:
            – Type: issn-print
              Value: 01695002
          Numbering:
            – Type: volume
              Value: 113
          Titles:
            – TitleFull: Lung Cancer (01695002)
              Type: main
ResultId 1